Molecular Basis of FAAH-Out Associated Pain Insensitivity
Abstract Chronic pain affects millions of people worldwide and new treatments are needed urgently. One way to identify novel analgesic...
top of page
THE SUFFERING ABOLITIONIST COMPANY
WHO WE ARE
The Far Out Initiative is a Public Benefit Biotechnology Company focused on developing technological solutions to the problem of involuntary suffering in human and non-human animals. We endeavor to accelerate the rate at which new – and old – scientific discoveries are translated into scalable altruistic interventions that can be rapidly implemented and disseminated through market-based strategies.
CORE TEAM
Passion. Expertise. Originality.
.png)
WHO IS JO CAMERON?
THE ANANDA LINES
​
We are currently investigating the deletion of the gene FAAH and the careful micro-deletion of portions of the pseudo-gene FAAH-OUT to replicate the near-complete immunity to physical and psychological pain recently discovered in a Scottish woman named Jo Cameron. We have successfully performed a micro-deletion of portions of FAAH-OUT in porcine somatic cells, and we're presently engaged in doing the same in mouse somatic cells.
The next phase of our research project will involve deleting FAAH and portions of FAAH-OUT in implantable mouse and rat embryos to create the world's first lines of animals that share Cameron's near-immunity to physical and psychological suffering.
THE ANANDA LINES: RODENT PHASE
There are four primary goals of the "rodent phase" of the Ananda Lines Project:
(1) To disrupt the industry that currently produces live mice and rats for consumption by snakes and reptiles by replacing wild-type mice and rats – which have a tremendous capacity for suffering – with extremely low suffering FAAH Platform knockouts that we expect will be nearly immune to both physical pain and states of psychological suffering, like fear, panic, and anxiety.
(2) To disrupt those portions of the test rodent market in which our genetic modifications don't represent a confounding variable, such as in the skin and eye testing of new consumer products and chemicals.
(3) To create "in-home ambassadors" for FAAH Platform mediated suffering reduction technology. Knocking out FAAH and select portions of FAAH-Subsequent pseudo-gene will substantially increase the level of circulating anandamide ("the bliss molecule"), which is known to decrease the fear response substantially and mediate the feeling of social reward connected with oxytocin signaling. We expect this to lead to animals with radically less fear-driven reactive aggression and a substantially increased tendency to seek out social contact, making them exceptionally desirable as small pets.
(4) To leverage the profits and media exposure produced by entering the above three markets to achieve early self-sustaining profitability for The Far Out Initiative and to finance the more complex "farm animal" stage of the Ananda Lines Project.
THE ANANDA LINES: FARM ANIMAL PHASE
The farm animal phase of the Ananda Lines Project represents the highest animal-focused ambition of The Far Out Initiative: to begin to disrupt the meat industry and thereby alleviate the tremendous suffering occurring in factory farms around the globe.
We have identified several markets in South America that have regulations that would classify gene knockout animals with no added foreign DNA not as "genetically modified organisms" (GMOs) but as animals produced through a "new breeding technique" (NBT). And with this difference in classification comes substantially decreased regulatory barriers to the meat market. These are the markets of Brazil (the world's largest cattle producer), Argentina, Ecuador, and Paraguay.
As one can verify through the below link to the Genetic Literacy Project's survey of national regulatory schemes, all four of these nations rate a 10 out of 10 for the liberality of their laws regulating genetically altered animals.
Following them are the regulatory schemes of the nations of Japan, Australia, and Canada, which all rate an 8 out of 10 on the regulatory survey.
The combined yearly revenue of these meat markets is more than 130 Billion USD, so even a minimal degree of market penetration could result in a tremendously high yearly revenue for The Far Out Initiative.
LINK: The Genetic Literacy Project Survey
UPDATE: The UK recently passed legislation allowing gene-edited ("precision bred") farm animals containing no species-foreign genes to enter the food supply, likely without GMO labeling. Moreover, this legislation would allow for gene-edited pets to enter the market. A direct link to the legislation is underlined below. It looks increasingly likely that our initial market launch will happen in the UK.
Statista said yearly revenue in the UK meat market was US$30.01 in 2023. The market is expected to grow annually by 3.98% (CAGR 2023-2028).
LINK: The UK's Genetic Technology (Precision Breeding) Bill
The Metta Project is our human-directed research effort intended to radically accelerate the arrival of the post-suffering era.
Phase 1: Research a Multi-Drug Approach
The two core genetic mutations that impact the FAAH/FAAH-OUT platform and lead to "Feel Good Syndrome" have a downstream effect on the expression of many genes. However, fewer than a handful of these genes directly relate to physical and psychological suffering. Targeting the proteins these genes code for using a set of already discovered inhibitory compounds is possible, plausibly replicating the synergistic biological interactions that generate the nearly suffering-free phenotype seen in "Feel Good Syndrome."
Jo Cameron and her late father prove that this set of synergistic biological interactions can lead to lifelong extreme well-being while allowing for a healthy, fertile phenotype capable of surviving into late old age.
However, we will investigate the possibility of off-site interactions between the compounds. So, we will conduct basic animal toxicology testing before self-testing this set of compounds under double-blind conditions in a nation where such self-testing is permissible, gathering detailed human-derived data throughout the process.
If successful, not only will we have established that a lucidity and functionality-preserving pharmacological solution to the problem of human suffering is possible, but we will also have provided the world with the means to end the opioid crisis, for FAAH-inhibition - one aspect of our strategy - prevents and reverses opioid tolerance. Moreover, we will have provided the world with a solution to the chief driver of all drug abuse: intolerable suffering.
Following the likely success of this research program, we will make all of our data open-source - including detailed synthesis instructions for all compounds utilized - and send a press release to as many science journalists as possible.
Note: This is a purely altruistic research project - we will not be able to profit from it. If you are interested in supporting this research, please get in touch with us.
Phase 2: Direct Genetic Intervention
Other organizations are already conducting human genetic interventions in regions of the world with liberal regulations. When organizational growth and technology permit, we will self-test a genetic intervention replicating the genetic basis of permanent "Feel Good Syndrome" and later make this intervention available to wealthy early adopters.
We will use virtually all funding that we acquire by doing so to make this intervention freely available to those among us who are the most in need of it, i.e., people with conditions that lead to chronic and acute physical or psychological pain.
Address
8 The Green, STE 10525, Dover, Delaware 19901
(+1) 540-541-9308
Invest
Simple agreement for future equity (SAFE) contracts available! Help us to accelerate our mission!
bottom of page